Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ)
- Previous Close
80.91 - Open
80.01 - Bid 80.75 x --
- Ask 80.76 x --
- Day's Range
79.07 - 80.85 - 52 Week Range
59.55 - 94.28 - Volume
2,794,379 - Avg. Volume
4,622,560 - Market Cap (intraday)
28.334B - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
28.62 - EPS (TTM)
2.82 - Earnings Date Apr 25, 2025 - Apr 28, 2025
- Forward Dividend & Yield 1.80 (2.22%)
- Ex-Dividend Date Jun 28, 2024
- 1y Target Est
86.15
Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; provision of chemical macromolecule contract development manufacture organization (CDMO) solutions for polypeptides, oligonucleotides, glycans, toxins-linkers and other macromolecules; biosynthesis solutions; biologics CDMO solutions for monoclonal antibodies and antibody-drug conjugates; and contract research organization solutions and messenger RNA solutions. In addition, the company is involved in development and drug product manufacturing; provision of pharmaceutical analysis and testing services; medical research and development; manufacturing, sale, and development of medicine raw materials and relevant products; sale of drug products; pharmaceuticals and chemical manufacturing; wholesaling and retailing of drugs; sale, import and export trade; information technology; technology development; and research and experimental development activities. The company was founded in 1998 and is headquartered in Tianjin, China.
www.asymchem.com.cnRecent News: 002821.SZ
View MorePerformance Overview: 002821.SZ
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002821.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002821.SZ
View MoreValuation Measures
Market Cap
28.34B
Enterprise Value
21.09B
Trailing P/E
28.69
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.79
Price/Book (mrq)
1.70
Enterprise Value/Revenue
3.55
Enterprise Value/EBITDA
18.39
Financial Highlights
Profitability and Income Statement
Profit Margin
16.71%
Return on Assets (ttm)
2.29%
Return on Equity (ttm)
5.64%
Revenue (ttm)
5.95B
Net Income Avi to Common (ttm)
993.59M
Diluted EPS (ttm)
2.82
Balance Sheet and Cash Flow
Total Cash (mrq)
7.82B
Total Debt/Equity (mrq)
1.85%
Levered Free Cash Flow (ttm)
-481.74M